Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by jfm1330on Jul 07, 2021 2:58pm
210 Views
Post# 33506438

RE:RE:RE:RE:RE:RE:RE:RE:Volume pickup last 45 mins

RE:RE:RE:RE:RE:RE:RE:RE:Volume pickup last 45 minsA possible NASH approval would come only in four to five years and it would cost a lot of money to get there and it will not drive the SP until some positive interim data. Oncology is a totally different ball game. If it works, the will be a flow of interim data and news, partnerships with proprietary drugs, new PDCs with generic drugs or radioisotopes, and a lot of different new clinical trials on different types of cancer, breakthrough therapy, accelerated approval, etc...

If oncology is really a breakthrough technology, I would not be surprised to see them drop NASH or to partner it if they can find a company willing to invest in it. We are not there yet. It will all depend on potential good results in oncology and how good these results could be.


CreatingApe wrote:
what do you think...With a marketing ace from PFIZER as our new CEO? Also do you think a life saving cancer treatment and life saving nash treatment will sell more easily than a niche drug for people who have HIV and want tighter stomachs?? Tired of the Thera cant sell drugs complaints. This is a whole other ball game now. New leader and targeting much more aggresive markets. If either drug gets approval we hit the lottery.


<< Previous
Bullboard Posts
Next >>